FDA Fast-Track Fuels Outlook Therapeutics Rally, Though Sparse Volume Gives Pause

Outlook Therapeutics shares jump 30% after FDA grants priority Class 1 review for ONS-5010, setting a July 29 verdict. Caution: low volume rally and overbought conditions.

A two-day surge has propelled shares of Outlook Therapeutics sharply higher, with the stock gaining 14.7% on Wednesday and another 16% on Thursday to trade around $1.84. The catalyst? A deadline that now carries an extra dose of urgency: the U.S. Food and Drug Administration has granted the company’s resubmitted application for ONS-5010 a priority “Class 1” review, slashing the typical evaluation window to roughly 60 days. The regulator is set to deliver its verdict on July 29, 2026.

Investors were quick to bid up the stock, but beneath the surface lies a cautionary signal. Thursday’s rally occurred on trading volume that amounted to only a fraction of the daily average — a pattern that often raises questions about the durability of the move. The sharp ascent has also pushed the shares into deeply overbought territory, and the stock is now testing a key resistance level near $2.00, a hurdle it has yet to clear.

The road to this point has been anything but smooth. The FDA rejected ONS-5010 twice in previous cycles. Outlook Therapeutics successfully appealed the second rejection earlier this year, forcing the agency to re-examine the drug, which would become the first FDA-approved ophthalmic formulation of bevacizumab if greenlit. The treatment targets wet age-related macular degeneration, a leading cause of vision loss in older adults. Already authorized in the European Union and the United Kingdom, a U.S. approval would open a much larger commercial opportunity.

On the regulatory front, the company has also resolved a separate formal dispute with the FDA, paving the way for the current resubmission. That de-escalation was followed in June by insider buying: a member of the board of directors purchased a notable block of shares, according to regulatory filings, signaling confidence from inside the corner office.

Financially, Outlook Therapeutics remains a classic development-stage biotech. In its most recent quarter, the company generated roughly $1.4 million in revenue and posted a net loss of about $4.5 million. EBITDA stayed negative. To bridge the gap to the FDA decision, the firm raised fresh capital through a share placement in May, providing enough runway to cover operations through the verdict.

One positive development has been the stock’s recovery from perilously low levels. Earlier this year, a sustained slide brought the shares below $1.00, threatening Nasdaq’s minimum bid-price requirement and raising delisting fears. But the June rally lifted the stock above that threshold for ten consecutive trading days, restoring compliance and removing an overhang that had weighed on sentiment since early 2024.

Chart watchers note that the stock has established a support zone around $1.60, which held during the recent pullback. A clear break above the $2.00 resistance could open the door to further gains, but the definitive catalyst remains the FDA’s decision. Until July 29, every tick higher will be measured against the risk that trading thinness and overbought conditions may leave the stock vulnerable to a sharp reversal — regardless of which way the regulatory winds blow.